ReviewJournal of cachexia, sarcopenia and muscle2023
Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments.
Review in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- BLOBFISH: bipartite limited subnetworks from multiple observations using breadth-first search with constrained hops.Bioinformatics (Oxford, England) · 2026Article
- LaminA/C-dependent cellular senescence signaling promotes skeletal muscle atrophy and abnormalities in Parkinson's disease.Cell death & disease · 2026Article
- The taste of Parkinson's: How food choices reflect nutritional health.Journal of Parkinson's disease · 2026Article
- Automated volumetric MRI quantification of body fat and skeletal muscle in the UK Biobank: technical validation against expert manual segmentations and comparison with single-slice techniques.Abdominal radiology (New York) · 2026Article
- Age-related transcriptional drift and physiological adaptation in long-living Ames dwarf skeletal muscle.NAR molecular medicine · 2026Article
- Prevalence of low muscle mass and its association with orthostatic hypotension and related symptoms in Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Reprogramming brain-resident macrophages: from disease drivers to therapeutic allies in neurological disorders.Frontiers in cellular neuroscience · 2026Review
- Physical exercise as a precision strategy for targeted PINK1 recruitment- a mechanistic review.Frontiers in physiology · 2026Review
- Parkinson's Disease and Frailty: A Two-Way Link Across Aging.Journal of clinical medicine · 2025Review
- Vital nutrition: enhancing health in advanced Parkinson's disease with device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Maximum Muscle Output and Electromyographic Activity of Masticatory Muscles in Persons With Parkinson's Disease. A Case-Control Study.Journal of oral rehabilitation · 2025Article
- Pervasive glycative stress links metabolic imbalance and muscle atrophy in early-onset Parkinson's disease.Molecular metabolism · 2025Article
- Oxidative Stress in Neurodegenerative Disorders: A Key Driver in Impairing Skeletal Muscle Health.International journal of molecular sciences · 2025Review
- Long-term multicomponent exercise enhances functional mobility in early-stage Parkinson's disease: a 48-month retrospective cohort study.Frontiers in physiology · 2025Article
- Asymmetry in Atypical Parkinsonian Syndromes-A Review.Journal of clinical medicine · 2024Review
- Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments.Journal of cachexia, sarcopenia and muscle · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is increasing evidence that neurodegenerative disorders including the Parkinsonian syndromes are associated with impaired skeletal muscle health, manifesting as wasting and weakness. Many of the movement problems, lack of muscle strength and reduction in quality of life that are characteristic of these syndromes can be attributed to impairments in skeletal muscle health, but this concept has been grossly understudied and represents an important area of unmet clinical need. This review describes the changes in skeletal muscle health in idiopathic Parkinson's disease and in two atypical Parkinsonian syndromes, the most aggressive synucleinopathy multiple system atrophy, and the tauopathy progressive supranuclear palsy. The pathogenesis of the skeletal muscle changes is described, including the contribution of impairments to the central and peripheral nervous system and intrinsic alterations. Pharmacological interventions targeting the underlying molecular mechanisms with therapeutic potential to improve skeletal muscle health in affected patients are also discussed. Although little is known about the mechanisms underlying these conditions, current evidence implicates multiple pathways and processes, highlighting the likely need for combination therapies to protect muscle health and emphasizing the merit of personalized interventions for patients with different physical capacities at different stages of their disease. As muscle fatigue is often experienced by patients prior to diagnosis, the identification and measurement of this symptom and related biomarkers to identify early signs of disease require careful interrogation, especially for multiple system atrophy and progressive supranuclear palsy where diagnosis is often made several years after onset of symptoms and only confirmed post-mortem. We propose a multidisciplinary approach for early diagnosis and implementation of personalized interventions to preserve muscle health and improve quality of life for patients with typical and atypical Parkinsonian syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.